NOVO NORDISK

Fangzhou Inc., China's leading online chronic disease management platform serving 49.2 million registered users, has signed a Memorandum of Understanding with Novo Nordisk to collaborate on managing diabetes and obesity through AI-powered solutions.

Bristol Myers Squibb and Pfizer announced a new direct-to-patient purchasing option for Eliquis (apixaban) through their Eliquis 360 Support program, offering eligible patients a cash price more than 40% below the current $606 list price.

Hengrui Pharma and Kailera Therapeutics' dual-acting obesity drug HRS9531 demonstrated 18% weight loss in a Phase 3 trial in China, significantly outperforming placebo by 16%.

Cipla is preparing to enter India's weight management segment to address rising demand for effective obesity solutions, as announced by CEO Umang Vohra in the company's 2024-25 annual report.

Italian authorities appointed a special commissioner to expedite Novo Nordisk's promised 2 billion-euro ($2.34 billion) investment in a factory south of Rome that will produce weight loss and diabetes drugs.

Biocon Ltd. is seeking regulatory approval for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting Canada as its first major market entry by 2026.

Protagonist Therapeutics has selected PN-477, a novel triple agonist peptide targeting GLP-1, GIP, and GCG receptors, as a development candidate for obesity treatment with both oral and injectable formulations.

Cellarity has dosed the first patient in a Phase 1 clinical trial of CLY-124, a novel oral medicine that increases fetal hemoglobin through a globin-switching mechanism to treat sickle cell disease.

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion to update Ozempic's label to include peripheral artery disease indications.

Novo Nordisk's phase 3b FRONTIER5 trial demonstrated that patients with hemophilia A can safely switch directly from emicizumab to investigational Mim8 prophylaxis without requiring a washout period.